LoginRegister
    Beximco Pharma announces Commercial Agreement with Mylan in BangladeshBeximco Pharma announces Commercial Agreement with Mylan in Bangladesh
    FDA authorizes marketing of the first genetic test for Fragile X SyndromeFDA authorizes marketing of the first genetic test for Fragile X Syndrome
    SoftBank leads USD 165 million capital boost for liquid biopsy firm KariusSoftBank leads USD 165 million capital boost for liquid biopsy firm Karius
    Novartis announces FDA and EMA filing acceptance of ofatumumab, for treatment of relapsing form of MSNovartis announces FDA and EMA filing acceptance of ofatumumab, for treatment of relapsing form of...
    BA/BE study applications have to be processed in 15 days: CDSCOBA/BE study applications have to be processed in 15 days: CDSCO
    Aurobindo Pharma gets USFDA nod for Azithromycin 250 mg and 500 mgAurobindo Pharma gets USFDA nod for Azithromycin 250 mg and 500 mg
    USV not dominant player, hence no case: CCI dismisses petition by pharma wholesalerUSV not dominant player, hence no case: CCI dismisses petition by pharma wholesaler
    Coronavirus: Restrictions imposed on the export of medical equipment to ChinaCoronavirus: Restrictions imposed on the export of medical equipment to China
    Solara Puducherry and Mangalore facilities complete USFDA Inspection with zero 483s observationsSolara Puducherry and Mangalore facilities complete USFDA Inspection with zero 483s observations
    Biocons Insulin Manufacturing Facility in Malaysia Completes USFDA inspection with three observationsBiocon's Insulin Manufacturing Facility in Malaysia Completes USFDA inspection with three...
    USFDA approves Eli Lillys Trulicity (dulaglutide) for reduction in MACE in type 2 diabetes patientUSFDA approves Eli Lilly's Trulicity (dulaglutide) for reduction in MACE in type 2 diabetes patient
    AIIMS director kickstarts three day International Conference at Delhi Pharmaceutical Sciences and Research UniversityAIIMS director kickstarts three day International Conference at Delhi Pharmaceutical Sciences and...
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X